论文部分内容阅读
目的观察治疗HIV/结核分枝杆菌(Mycobacterium tuberculosis,MTB)合并感染的临床疗效。方法分析126例HIV/MTB合并感染者的临床疗效,统计高效抗反转录病毒治疗(highly active antiretroviral therapy,HAART)后1年内免疫重建炎症反应综合征(immune reconstitution inflammatory syndrome,IRIS)发病率及CD4+T淋巴细胞上升水平。结果 126例均完成了抗结核治疗,HAART 1年内无死亡及复发结核病例。HAART后CD4+T淋巴细胞计数逐渐升高,以12周时上升幅度最大。治疗过程中37例(29.37%)出现IRIS。CD4+T淋巴细胞计数<200个/mm3组IRIS发病率高于≥200个/mm3组(χ2=6.206,P=0.013),且在HAART后12周及48周CD4+T淋巴细胞上升幅度低于≥200个/mm3组(P<0.05)。结论 HIV/MTB合并感染者在CD4+T淋巴细胞≥200个/mm3时接受HAART,IRIS发病率低,免疫重建良好。
Objective To observe the clinical effect of treating HIV / Mycobacterium tuberculosis (MTB) complicated with infection. Methods The clinical efficacy of 126 HIV / MTB co-infected patients was analyzed. The incidence of immune reconstitution inflammatory syndrome (IRIS) within 1 year after highly active antiretroviral therapy (HAART) CD4 + T lymphocytes rise. Results All of the 126 patients completed anti-TB treatment. There was no death and recurrent tuberculosis within 1 year of HAART. After HAART CD4 + T lymphocyte counts gradually increased, the largest increase at 12 weeks. In the course of treatment, 37 cases (29.37%) had IRIS. The incidence of IRIS in CD4 + T lymphocyte count <200 / mm3 group was higher than ≥200 / mm3 group (χ2 = 6.206, P = 0.013), and the increase rate of CD4 + T lymphocytes at 12 weeks and 48 weeks after HAART was low In ≥ 200 / mm3 group (P <0.05). Conclusion HIV / MTB co-infected patients received HAART with CD4 + T lymphocytes ≥200 / mm3. The incidence of IRIS is low and immune reconstitution is good.